Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ACRX Roth Capital Remains Neutral On Acelrx Pharmaceuticals Following 3Q14 Update http://www.smarteranalyst.com/2014/11/14/roth-capital-remains-neutral-on-acelrx-pharmaceuticals-following-3q14-update/
$ACRX Roth Capital Remains Neutral On Acelrx Pharmaceuticals Following 3Q14 Update http://www.smarteranalyst.com/2014/11/14/roth-capital-remains-neutral-on-acelrx-pharmaceuticals-following-3q14-update/
$LPTN MLV Reiterates Buy On Lpath Following 3Q Earnings Update http://www.smarteranalyst.com/2014/11/13/mlv-reiterates-buy-on-lpath-following-3q-earnings-update/
$PLUG Roth Capital Maintains Neutral On Plug Power As Q3 Results Were Largely Disappointing http://www.smarteranalyst.com/2014/11/13/roth-capital-maintains-neutral-on-plug-power-as-q3-results-were-largely-disappointing/
$PLUG Roth Capital Maintains Neutral On Plug Power As Q3 Results Were Largely Disappointing http://www.smarteranalyst.com/2014/11/13/roth-capital-maintains-neutral-on-plug-power-as-q3-results-were-largely-disappointing/
$RNN Roth Capital Maintains Buy On Rexahn Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/13/roth-capital-maintains-buy-on-rexahn-pharmaceuticals-following-3q14-results/
$SRPT Roth Capital Maintains Buy On Sarepta Following First Patient Dosed In Study Of Eteplirsen http://www.smarteranalyst.com/2014/11/13/roth-capital-maintains-buy-on-sarepta-following-first-patient-dosed-in-study-of-eteplirsen/
$TGTX Brean Capital Maintains Buy On TG Therapeutics Following 3Q14 Update http://www.smarteranalyst.com/2014/11/13/brean-capital-maintains-buy-on-tg-therapeutics-following-3q14-update/
Fate Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/13/fate-therapeutics-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$TWTR Cantor Comments On Twitter Following Analyst Day; Keeps $58 PT http://www.smarteranalyst.com/2014/11/13/cantor-comments-on-twitter-following-analyst-day-keeps-58-pt/
$TWTR Cantor Comments On Twitter Following Analyst Day; Keeps $58 PT http://www.smarteranalyst.com/2014/11/13/cantor-comments-on-twitter-following-analyst-day-keeps-58-pt/
$TGTX TG Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/13/tg-therapeutics-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$THLD H.C. Wainwright Reiterates Buy On Threshold Pharmaceuticals, Sees 264% Upside For The Stock http://www.smarteranalyst.com/2014/11/13/h-c-wainwright-reiterates-buy-on-threshold-pharmaceuticals-sees-264-upside-for-stock/
H.C. Wainwright Reiterates Buy On Threshold Pharmaceuticals, Sees 264% Upside For The Stock http://www.smarteranalyst.com/2014/11/13/h-c-wainwright-reiterates-buy-on-threshold-pharmaceuticals-sees-264-upside-for-stock/
$CSIQ Roth Capital Reiterates Buy On Canadian Solar Following Strong Q3 Beat http://www.smarteranalyst.com/2014/11/13/roth-capital-reiterates-buy-on-canadian-solar-following-strong-q3-beat/
$CSIQ Roth Capital Reiterates Buy On Canadian Solar Following Strong Q3 Beat http://www.smarteranalyst.com/2014/11/13/roth-capital-reiterates-buy-on-canadian-solar-following-strong-q3-beat/
?$OXGN H.C. Wainwright Reiterates Buy On OXiGENE Following 3Q14 Results http://www.smarteranalyst.com/2014/11/13/h-c-wainwright-reiterates-buy-on-oxigene-following-3q14-results/
$MEIP Brean Capital Maintains Buy On MEI Pharma Shares, $16 PT http://www.smarteranalyst.com/2014/11/12/brean-capital-maintains-buy-on-mei-pharma-shares-16-pt/
$GALT MLV Reiterates Buy On Galectin Therapeutics On The Back Of 3Q14 Update http://www.smarteranalyst.com/2014/11/12/mlv-reiterates-buy-on-tg-therapeutics-following-3q14-update/
$TGTX MLV Reiterates Buy On TG Therapeutics Following 3Q14 Update http://www.smarteranalyst.com/2014/11/12/mlv-reiterates-buy-on-tg-therapeutics-following-3q14-update/
$PPHM MLV Reiterates Buy On Peregrine As Phase II Clinical Data Presented At SITC http://www.smarteranalyst.com/2014/11/12/mlv-reiterates-buy-on-peregrine-as-phase-ii-clinical-data-presented-at-sitc/
$PPHM MLV Reiterates Buy On Peregrine As Phase II Clinical Data Presented At SITC http://www.smarteranalyst.com/2014/11/12/mlv-reiterates-buy-on-peregrine-as-phase-ii-clinical-data-presented-at-sitc/
$HK MLV Cuts Halcon Resources Price Target On Reduced Activity http://www.smarteranalyst.com/2014/11/12/mlv-cuts-halcon-resources-price-target-on-reduced-activity/
$TTPH Brean Capital Reiterates Buy On Tetraphas Shares, Sees 5% Downside http://www.smarteranalyst.com/2014/11/12/brean-capital-reiterates-buy-on-tetraphas-shares-sees-5-downside/
$SGYP Cantor Reiterates Buy On Synergy Pharmaceuticals As 3Q14 Expenses Came In Below Expectations http://www.smarteranalyst.com/2014/11/12/cantor-reiterates-buy-on-synergy-pharmaceuticals-as-3q14-expenses-came-in-below-expectations/
$GALE Maxim Group Maintains Buy On Galena Following First Patient Dosed In Phase 2 Trial http://www.smarteranalyst.com/2014/11/12/maxim-group-maintains-buy-on-galena-following-first-patient-dosed-in-phase-2-trial/
$GALE Maxim Group Maintains Buy On Galena Following First Patient Dosed In Phase 2 Trial http://www.smarteranalyst.com/2014/11/12/maxim-group-maintains-buy-on-galena-following-first-patient-dosed-in-phase-2-trial/
$DDD William Blair Reiterates Underperform On 3D Systems Following 3Q14 Results http://www.smarteranalyst.com/2014/11/12/william-blair-reiterates-underperform-on-3d-systems-following-3q14-results/
$DDD William Blair Reiterates Underperform On 3D Systems Following 3Q14 Results http://www.smarteranalyst.com/2014/11/12/william-blair-reiterates-underperform-on-3d-systems-following-3q14-results/
$MACK Oppenheimer Comments On Merrimack Pharmaceuticals: Slight NDA Delay Nothing Too Concerning http://www.smarteranalyst.com/2014/11/12/oppenheimer-comments-on-merrimack-pharmaceuticals-slight-nda-delay-nothing-too-concerning/
$NPSP Oppenheimer Reiterates Outperform On NPS Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/12/oppenheimer-reiterates-outperform-on-nps-pharmaceuticals-following-3q14-results/
$OPK Oppenheimer Reiterates Outperform On Opko Health Following 3Q14 Results http://www.smarteranalyst.com/2014/11/12/oppenheimer-reiterates-outperform-on-opko-health-following-3q14-results/
$JNPR Oppenheimer Comments On Juniper Networks Following CEO Transition http://www.smarteranalyst.com/2014/11/12/oppenheimer-comments-on-juniper-networks-following-ceo-transition/
$JNPR Oppenheimer Comments On Juniper Networks Following CEO Transition http://www.smarteranalyst.com/2014/11/12/oppenheimer-comments-on-juniper-networks-following-ceo-transition/
$CALL Oppenheimer Reiterates Perform On Vocaltec Communications Following Weak 3Q14 http://www.smarteranalyst.com/2014/11/12/oppenheimer-reiterates-perform-on-vocaltec-communications-following-weak-3q14/
$DDD 3D Systems: With No New Gremlins In Final 3Q14 Results, The Bottoming Story Is Intact, Says Oppenheimer http://www.smarteranalyst.com/2014/11/11/3d-systems-with-no-new-gremlins-in-final-3q14-results-the-bottoming-story-is-intact-says-oppenheimer/
$DDD 3D Systems: With No New Gremlins In Final 3Q14 Results, The Bottoming Story Is Intact, Says Oppenheimer http://www.smarteranalyst.com/2014/11/11/3d-systems-with-no-new-gremlins-in-final-3q14-results-the-bottoming-story-is-intact-says-oppenheimer/
$SNSS Roth Capital Maintains Neutral On Sunesis, Sees 24% Downside http://www.smarteranalyst.com/2014/11/11/roth-capital-maintains-neutral-on-sunesis-sees-24-downside/
$PLNR Planar: Shares Have Reached Full Valuation, Says Roth Capital http://www.smarteranalyst.com/2014/11/11/planar-shares-have-reached-full-valuation-says-roth-capital/
$NEO Roth Capital Reiterates Buy On NeoGenomics Ahead Of Investor Meetings With Management http://www.smarteranalyst.com/2014/11/11/roth-capital-reiterates-buy-on-neogenomics-ahead-of-investor-meetings-with-management/